Compulsory Licensing: A Study with Reference to India’s First Pharmaceutical Compulsory License Case of Natco vs. Bayer

20 Pages Posted: 15 Sep 2012

Date Written: September 14, 2012

Abstract

Recent judgment by India on compulsory License of Bater's Patented cancer drug Nexavar to Indian generic company Natco is potentially a game changer for whole pharmaceutical industry. This paper examines if India is TRIPS compliant while use the TRIPS flexibility of CL.

Keywords: Natco, Compulsory License, TRIPS, India, Bayer, Nexavar, Cipla, flexibility, patent, pharmaceutical

JEL Classification: K11, K33, K41

Suggested Citation

Mathur, Charu, Compulsory Licensing: A Study with Reference to India’s First Pharmaceutical Compulsory License Case of Natco vs. Bayer (September 14, 2012). Available at SSRN: https://ssrn.com/abstract=2146821 or http://dx.doi.org/10.2139/ssrn.2146821

Charu Mathur (Contact Author)

Supreme Court of India ( email )

Tilak Marg
New Delhi, Delhi 110201
India
9868009602 (Phone)

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
717
Abstract Views
3,028
Rank
66,168
PlumX Metrics